U.S. Stock Night Market Opening Movements

CrowdStrike fell 10.65% in after-hours trading. Based on recent key news:

1. On June 3, CrowdStrike announced its Q1 fiscal year 2027 earnings report. Although revenue and adjusted earnings per share exceeded market expectations, operating expenses increased by 15%, leading to a decline of about 10% in after-hours trading. The company expects full-year revenue to be between $5.91 billion and $5.96 billion, with adjusted earnings per share between $4.88 and $4.96. Source: Reuters

2. On June 3, CrowdStrike announced that the board approved a four-for-one stock split, with each shareholder receiving an additional three shares at the close of trading on June 25. Following this announcement, the stock price fell about 8% in after-hours trading. Source: Benzinga

3. On June 3, U.S.-China diplomatic tensions escalated, affecting market sentiment for tech stocks and supply chain challenges. U.S. President Trump downplayed the threat of mines in the Strait of Hormuz, but other officials remained cautious about the threat from Iranian drones, further increasing market uncertainty. Source: Zhitong Finance. Tech stocks have performed strongly recently, but market sentiment remains cautious.

Jianzhi Edu Tech fell 9.26% in after-hours trading. Based on recent key news:

1. On June 2, Jianzhi Edu Tech announced a partnership with SeaArt AI to integrate generative AI tools into its online learning platform. This news failed to boost market confidence, and the stock price continued to decline.

2. On June 3, Jianzhi Edu Tech completed a $5 million registered direct offering at a price of $1 per ADS. Despite raising funds, market concerns about its future profitability led to a decline in the stock price.

3. On June 3, technical analysis showed that Jianzhi Edu Tech's stock price was far below multiple moving averages, reflecting market pessimism about its prospects, with the stock price falling 41.70% in pre-market trading. The education industry faces challenges in digital transformation.

Top Gainers in U.S. Stock Night Market

Tilly's rose 12.61% in after-hours trading. Based on recent key news:

1. On June 3, Tilly's announced its Q1 2026 earnings report, with sales growth of 15.9% and a significant reduction in net loss. Strong performance in e-commerce and stores drove the stock price up. Source: Business Wire

2. On June 3, Tilly's expects sales to continue growing in the second quarter and is likely to achieve profitability. Despite facing inflation and consumer trend risks, the market holds an optimistic view of its prospects. Source: SEC 8-K report

3. On June 3, Tilly's same-store sales increased by 22.9% year-over-year, with net loss improving by $14.2 million year-over-year. Strong sales and profit margin expectations supported the rise in stock price. Source: MarketBeat. The retail industry is performing strongly overall, with significant growth in e-commerce Verastem rose 7.73% in after-hours trading. Based on recent key news:

4. On June 3, Verastem announced that its oral drug VS-7375 received Fast Track designation from the U.S. FDA for the treatment of locally advanced or metastatic non-small cell lung cancer with KRAS G12D mutation. This news drove the stock price up, as the drug is seen as a potential best-in-class treatment option.

5. On June 3, Verastem launched the Phase 2 TARGET-D 202 trial for advanced non-small cell lung cancer. This move demonstrates the company's positive progress in research and development, enhancing market confidence.

6. On June 3, Verastem's KRAS G12D inhibitor showed good safety and regulatory momentum in Phase II trials, further supporting the rise in stock price. The biopharmaceutical industry has seen significant R&D progress.

Jasper Therapeutics rose 5.43% in after-hours trading. Based on recent key news:

1. On June 1, Jasper Therapeutics announced that it is exploring strategic options, including a potential sale, to maximize shareholder value. The company is developing the experimental drug briquilimab for mast cell-driven diseases and stated that the board will evaluate options such as asset sales, licensing, partnerships, mergers, or company sales, while considering possible cost-cutting measures to maintain cash flow and compliance. This news drove the stock price up by 5%. Source: EDGAR system disclosure. The biotechnology industry has been quite volatile recently